• LifeTech Scientific posted a net loss attributable to owners of RMB 34.3 million, swinging from profit; basic loss per share was RMB 0.8 cents.
• Revenue fell 11.2% to RMB 600.8 million, while gross profit slipped 6.4% to RMB 465.9 million.
• Operating loss was RMB 11.3 million, versus operating profit a year earlier; other income and losses turned to a RMB 19.7 million loss.
• Excluding non-recurring items, net profit attributable to owners was RMB 114.8 million, down 51.9%, on lower revenue and net exchange losses.
• Board proposed no interim dividend; revenue mix shifted as structural heart fell to RMB 200.1 million while peripheral vascular rose to RMB 400.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12303908), on August 28, 2026, and is solely responsible for the information contained therein.